Abstract: Objective: To retrospectively analyze clinical efficacy and safety of concentrated growth factor（CGF）in the treatment of androgenetic alopecia （AGA). Methods: Sixty patients with moderate-to-severe AGA were collected including 48 in combination therapy group and 12 in CGF therapy group. All the patients were treated with AGA, once a month, for 3 times, and the patients in the combination therapy group were given additional topical minoxidil tincture, oral finasteride for male and spironolactone for female. The efficacy of the treatment were evaluated through the hair density and follicle unit density, the characteristics of the trichoscopic images, digital photographs and the global aesthetic improvement scale (GIAS). In addition, the number of patients with localized and systemic adverse reactions were recorded to assess the safety of the treatment. Results: Compared to pre-treatment, the mean follicle unit density in the CGF combination treatment group and CGF treatment group increased by 18.04±11.15 and 8.81±5.77 follicles/cm2 after treatment (Ps<0.05), and the hair density increased by 36.43±21.18 and 16.19±12.62 roots/cm2 (Ps<0.05). There was a significant difference in hair density  between the two groups (P<0.05), but there was no significant difference in follicle unit density improvement (P＞0.05). The improvement rates of perifollicular brown sign, yellow dot sign, and empty hair follicles were more than 70% in both groups , but none of the differences between the two groups were statistically significant. Both physician and patient satisfaction rates were upwards of 90% in two groups after the treatment. Only 2 of the 60 patients had obvious pain at the local injection area, and 3 experienced scalp itching. Conclusion: CGF is a safe and effective method for the treatment of androgenic alopecia, and the combined use of minoxidil tincture and finastericle or spironolactone is more effective.

Key words: concentrated growth factor, androgenetic alopecia, hair regrowth